Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review by Shirvalilou, Sakine et al.
Vol.:(0123456789) 
Journal of Neuro-Oncology 
https://doi.org/10.1007/s11060-021-03729-3
TOPIC REVIEW
Magnetic Hyperthermia as an adjuvant cancer therapy in combination 
with radiotherapy versus radiotherapy alone for recurrent/progressive 
glioblastoma: a systematic review
Sakine Shirvalilou1  · Samideh Khoei1,2 · Azam Janati Esfahani3 · Mahboobeh Kamali4 · Milad Shirvaliloo5 · 
Roghayeh Sheervalilou6 · Parvin Mirzaghavami2
Received: 9 January 2021 / Accepted: 27 February 2021 
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021
Abstract
Introduction Hyperthermia therapy (HT) is a recognized treatment modality, that can sensitize tumors to the effects of 
radiotherapy (RT) and chemotherapy by heating up tumor cells to 40–45 °C. The advantages of noninvasive inductive mag-
netic hyperthermia (MH) over RT or chemotherapy in the treatment of recurrent/progressive glioma have been confirmed 
by several clinical trials. Thus, here we have conducted a systematic review to provide a concise, albeit brief, account of the 
currently available literature regarding this topic.
Methods Five databases, PubMed/Medline, Embace, Ovid, WOS, and Scopus, were investigated to identify clinical studies 
comparing overall survival (OS) following RT/chemotherapy versus RT/chemotherapy + MH.
Results Eleven articles were selected for this systematic review, including reports on 227 glioma patients who met the study 
inclusion criteria. The papers included in this review comprised nine pilot clinical trials, one non-randomized clinical trial, 
and one retrospective investigation. As the clinical trials suggested, MH improved OS in primary glioblastoma (GBM), 
however, in the case of recurrent glioblastoma, no significant change in OS was reported. All 11 studies ascertained that no 
major side effects were observed during MH therapy.
Conclusion Our systematic review indicates that MH therapy as an adjuvant for RT could result in improved survival, com-
pared to the therapeutic outcomes achieved with RT alone in GBM, especially by intratumoral injection of magnetic nano-
particles. However, heterogeneity in the methodology of the most well-known studies, and differences in the study design 
may significantly limit the extent to which conclusions can be drawn. Thus, further investigations are required to shed more 
light on the efficacy of MH therapy as an adjuvant treatment modality in GBM.
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